TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24885755

Group type: EXPERIMENTAL
Intervention: IOERT with a median dose of 15 Gy, median electron energy of 6 MeV, median cone size of 9 cm
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative EBRT with a median dose of 46 Gy after IOERT or 60 Gy without IOERT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Postoperative EBRT
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Multimodal therapy including IOERT and postoperative EBRT
Number of subjects: 50
Study: 24885966

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lamotrigine
Number of subjects: 51
Study: 24886078

Group type: EXPERIMENTAL
Intervention: Sugar absorption test in FD patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sugar absorption test in controls
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Assessment of anxiety and depression in FD patients
Number of subjects: 19

Group type: COMPARATOR
Intervention: Assessment of anxiety and depression in controls
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Mast cell and eosinophil density assessment in FD patients
Number of subjects: 19
Study: 24886128

Group type: EXPERIMENTAL
Intervention: Weight loss intervention group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 24886192

Group type: EXPERIMENTAL
Intervention: Dietary ascorbic acid intake (100 mg/day higher)
Number of subjects: 7569

Group type: EXPERIMENTAL
Intervention: Dietary ascorbic acid intake
Number of subjects: 7569

Group type: EXPERIMENTAL
Intervention: High content of dietary ascorbic acid
Number of subjects: 7569
Study: 24886233

Group type: EXPERIMENTAL
Intervention: Use of biomarkers (MFAP4 and SP-D) for predicting COPD trajectory
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Data capture system from GPs' electronic patient records
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Yearly consultations and follow-up using data capture system
Number of subjects: 350
Study: 24886374

Group type: EXPERIMENTAL
Intervention: Intimate partner sexual aggression
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Intimate partner physical violence and sexual aggression
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Physically forced sex
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Non-physical coercive tactics
Number of subjects: 745
Study: 24886512

Group type: EXPERIMENTAL
Intervention: Everolimus treatment
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Everolimus treatment with positive expression of phospho-mTOR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Everolimus treatment with positive expression of phospho-S6RP
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Everolimus treatment with negative expression of phospho-4EBP1 and phospho-AKT
Number of subjects: 18
Study: 24886572

Group type: EXPERIMENTAL
Intervention: bio-optimized curcumin (Flexofytol®) 2x3 caps/day for 3 months
Number of subjects: 22
Study: 24886772

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 19
Study: 24887445

Group type: EXPERIMENTAL
Intervention: Multifaceted tailored intervention
Number of subjects: 0
Study: 24887615

Group type: EXPERIMENTAL
Intervention: Patient-Centered Medical Home (PCMH)
Number of subjects: 143489

Group type: COMPARATOR
Intervention: Paper Medical Records
Number of subjects: 143489

Group type: COMPARATOR
Intervention: Electronic Health Records (EHR) without PCMH
Number of subjects: 143489
Study: 24888813

Group type: EXPERIMENTAL
Intervention: GAA peptide vaccination with EphA2, IL-13Rα2, and survivin peptides emulsified in Montanide-ISA-51, administered subcutaneously every 3 weeks for eight courses, followed by booster vaccinations every 6 weeks.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: GAA peptide vaccination
Number of subjects: 26
Study: 24889179

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) at 250 mg/day for 24 weeks
Number of subjects: 19
Study: 24889281

Group type: EXPERIMENTAL
Intervention: Estimated blood glucose values
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Blood glucose testing
Number of subjects: 297
Study: 24889836

Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Epworth Sleepiness Scale (ESS)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Mobility measures (400-m walk time, SPPB score)
Number of subjects: 1635

Group type: EXPERIMENTAL
Intervention: Sedentary time
Number of subjects: 1635
Study: 24890385

Group type: EXPERIMENTAL
Intervention: TGF-β/Smad3 tumor-suppressor signature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGF-β
Number of subjects: 0

Group type: COMPARATOR
Intervention: TGF-β antagonists
Number of subjects: 0
Study: 24890823

Group type: EXPERIMENTAL
Intervention: Sitaxentan (6-week treatment)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (6-week treatment)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Nifedipine (6-week treatment)
Number of subjects: 27
Study: 24890858

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m² IV on d1, 4, 8, 11) and Doxorubicin (15 mg/m² IV on d1, 8) in 21-day cycles
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bortezomib plus Doxorubicin
Number of subjects: 38
Study: 24891019

Group type: EXPERIMENTAL
Intervention: Third assay (sandwich ELISA) for measuring glucagon concentrations
Number of subjects: 0

Group type: COMPARATOR
Intervention: C-terminal glucagon RIA
Number of subjects: 0
Study: 24891132

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: EEG monitoring
Number of subjects: 101
Study: 24891156

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 14
Study: 24891274

Group type: EXPERIMENTAL
Intervention: Decitabine (15 mg/m2 iv) and Vorinostat (230 mg/m2 PO div BID) followed by chemotherapy (vincristine, prednisone, PEG-asparaginase, doxorubicin)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Decitabine and Vorinostat
Number of subjects: 13
Study: 24891325

Group type: EXPERIMENTAL
Intervention: Lower dose hMSCs (5×10(6) hMSCs/kg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Higher dose hMSCs (10×10(6) hMSCs/kg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (PlasmaLyte A)
Number of subjects: 19
Study: 24891429

Group type: EXPERIMENTAL
Intervention: Mefloquine/artesunate (fixed-dose combination) administered orally once daily for 3 days
Number of subjects: 48
Study: 24892263

Group type: EXPERIMENTAL
Intervention: Etanercept (0.4 mg/kg, maximum 25 mg/dose) twice weekly for 4 to 8 weeks
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 34

Group type: COMPARATOR
Intervention: Topical corticosteroids (control)
Number of subjects: 34
Study: 24892422

Group type: EXPERIMENTAL
Intervention: Gammaplex (5% Intravenous Immunoglobulin, IVIg) at a dosage of 1 g/kg on two consecutive days
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Gammaplex (5% Intravenous Immunoglobulin, IVIg)
Number of subjects: 35
Study: 24893322

Group type: EXPERIMENTAL
Intervention: Blast exposure and/or mTBI (B/mTBI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No blast exposure or mTBI (No B/mTBI)
Number of subjects: 25
Study: 24893855

Group type: EXPERIMENTAL
Intervention: De-sialylated CD8 T cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CD103(+) CD8 T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tumor ST3Gal-II expression
Number of subjects: 0
Study: 24893962

Group type: EXPERIMENTAL
Intervention: 400 μg of sublingual misoprostol
Number of subjects: 481
Study: 24894084

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT) with two cycles of Epirubicin and Paclitaxel (Epi-Tax), followed by three consecutive HDCT cycles (one with Paclitaxel/Thiotepa (Thio-Tax) and two with Ifosfamide-Carboplatin-Etoposide regimen)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 45
Study: 24894668

Group type: EXPERIMENTAL
Intervention: exercise intervention
Number of subjects: 470
Study: 24895163

Group type: EXPERIMENTAL
Intervention: PESP present (ratio > 1)
Number of subjects: 941

Group type: COMPARATOR
Intervention: PESP absent
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Combination of PESP presence and LVEF ≤ 35%
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: GRACE score
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction (LVEF)
Number of subjects: 941

Group type: EXPERIMENTAL
Intervention: Number of recorded VPCs
Number of subjects: 941
Study: 24898091

Group type: EXPERIMENTAL
Intervention: Ultra-low dose (ULD) IL-2
Number of subjects: 40
Study: 24898305

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with cisplatin (75 mg/m(2), day 1) and docetaxel (75 mg/m(2), day 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2), 30-min infusion, day 1 every 3 weeks) with carboplatin (AUC6) and paclitaxel (200 mg/m(2), day 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Ombrabulin (35 mg/m(2))
Number of subjects: 69

Group type: COMPARATOR
Intervention: Cisplatin/docetaxel or carboplatin/paclitaxel (standard doses)
Number of subjects: 69
Study: 24898549

Group type: EXPERIMENTAL
Intervention: RG7155 (anti-CSF-1R antibody)
Number of subjects: 0
Study: 24898665

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tositumomab and iodine I-131 tositumomab
Number of subjects: 0
Study: 24898826

Group type: EXPERIMENTAL
Intervention: TET2 mutations
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: TET2 mutation status
Number of subjects: 215
Study: 24899155

Group type: EXPERIMENTAL
Intervention: Hypocaloric diet weight loss intervention
Number of subjects: 78
Study: 24900938

Group type: EXPERIMENTAL
Intervention: Daily interruption of continuous sedative and opioid infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intermittent sedation
Number of subjects: 60
Study: 24901360

Group type: EXPERIMENTAL
Intervention: Neoadjuvant gemcitabine 1000 mg/m intravenously over 100 minutes and oxaliplatin 80 mg/m intravenously over 2 hours, every 2 weeks.
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine 1000 mg/m intravenously over 30 minutes days 1, 8, and 15 every 4 weeks.
Number of subjects: 38
Study: 24901436

Group type: EXPERIMENTAL
Intervention: Septin9 DNA methylation based blood test (Epi proColon)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Combined results of Epi proColon and FIT
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Epi proColon test
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Both methods (Epi proColon and FIT)
Number of subjects: 301
Study: 24902119

Group type: EXPERIMENTAL
Intervention: Ulcerogenic medication
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 455

Group type: COMPARATOR
Intervention: Portal hypertension (measured by HVPG)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Liver cirrhosis (LC)
Number of subjects: 455
Study: 24903064

Group type: EXPERIMENTAL
Intervention: Catheter ablation
Number of subjects: 61
Study: 24903080

Group type: EXPERIMENTAL
Intervention: Nomogram based on the Ki-67 index
Number of subjects: 1848

Group type: COMPARATOR
Intervention: CS-IHC4 + nomogram score
Number of subjects: 1848
Study: 24903189

Group type: EXPERIMENTAL
Intervention: Imipenem 750 mg every 6 hours
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Imipenem 1000 mg every 8 hours
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Imipenem 1000 mg every 6 hours
Number of subjects: 51
Study: 24903199

Group type: EXPERIMENTAL
Intervention: Patient-centred care
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Increase in pregnancy rates
Number of subjects: 996
Study: 24903202

Group type: EXPERIMENTAL
Intervention: GnRH antagonist protocol with recombinant FSH (rFSH)
Number of subjects: 747
Study: 24903629

Group type: EXPERIMENTAL
Intervention: Lestaurtinib 80 mg twice daily for 18 weeks
Number of subjects: 39
Study: 24903795

Group type: EXPERIMENTAL
Intervention: Intermittent regimen of rifampin (RMP), pyrazinamide (PZA), and ethambutol (EMB) administered BIW or TIW for 6 months after initial daily doses.
Number of subjects: 98
Study: 24903982

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: CHA2DS2-VASc score
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: AVR with concomitant coronary artery bypass grafting
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Incident stroke
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Pre-AVR stroke rate
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Post-AVR stroke rate
Number of subjects: 1509
Study: 24904120

Group type: EXPERIMENTAL
Intervention: Oral ixazomib at maximum tolerated dose (MTD) of 2.97 mg/m(2) given weekly for 3 of 4 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral ixazomib at MTD of 2.97 mg/m(2).
Number of subjects: 60
Study: 24905490

Group type: EXPERIMENTAL
Intervention: Pegylated-interferon/ribavirin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL28B rs12979860 CC SNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ApoH and IL28B CC SNP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariate analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study: 24905567

Group type: EXPERIMENTAL
Intervention: Lower baseline stress
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Increased leisure-time physical activity (LTPA) from baseline to posttest
Number of subjects: 350
Study: 24905795

Group type: EXPERIMENTAL
Intervention: Platinum chromium everolimus-eluting stents (PtCr-EES)
Number of subjects: 196
Study: 24906304

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Ergonovine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Prostaglandin F2 alpha (PGF2α)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oxytocin in augmented labour
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oxytocin in non-augmented labour
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Oxytocin in absence of labour
Number of subjects: 46
Study: 24906361

Group type: EXPERIMENTAL
Intervention: Automated Fungitell assay
Number of subjects: 109

Group type: COMPARATOR
Intervention: Culture-negative samples
Number of subjects: 109
Study: 24906384

Group type: EXPERIMENTAL
Intervention: 124I and 18F-FDG PET/CT
Number of subjects: 100

Group type: COMPARATOR
Intervention: 131I therapy
Number of subjects: 100
Study: 24906637

Group type: EXPERIMENTAL
Intervention: Canakinumab (initial dose 150 mg or 300 mg, escalating up to 600 mg every 4 weeks)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Canakinumab (at maximum dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Canakinumab
Number of subjects: 6
Study: 24907095

Group type: EXPERIMENTAL
Intervention: Parental autistic tendency measured by Autism Spectrum Quotient (AQ)
Number of subjects: 491

Group type: EXPERIMENTAL
Intervention: Perceived family support and parental education
Number of subjects: 491
Study: 24907357

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Horse antithymocyte globulin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both antithymocyte globulins
Number of subjects: 0
Study: 24907633

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (neo-CRT) followed by surgery
Number of subjects: 28
Study: 24907635

Group type: EXPERIMENTAL
Intervention: Tremelimumab (15 mg/kg) plus gemcitabine (1000 mg/m² on days 1, 8, and 15 of each 28-day cycle)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Tremelimumab (6, 10, or 15 mg/kg) plus gemcitabine
Number of subjects: 34
Study: 24907636

Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF) (optimally dosed)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with granulocyte-macrophage colony-stimulating factor (GM-CSF) (suboptimally dosed)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: E75 (nelipepimut-S) vaccine with booster inoculations
Number of subjects: 195
Study: 24909546

Group type: EXPERIMENTAL
Intervention: TP-HD-HSV1/2 PCR
Number of subjects: 36
Study: 24909918

Group type: EXPERIMENTAL
Intervention: Parental experiences/needs during child's end-of-life care at home
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Provision of paediatric end-of-life care services in the home care setting
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through semi-structured interviews with parents
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Quantitative data about patient's characteristics from medical charts
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Statistical methods for data analysis
Number of subjects: 50
Study: 24911148

Group type: EXPERIMENTAL
Intervention: NiCord (UCB-derived cell product expanded for 21 days with nicotinamide)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Historical controls (not specified)
Number of subjects: 11
Study: 24911895

Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 228

Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 228

Group type: COMPARATOR
Intervention: PCV13
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Nonvaccine serotypes
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Serotype 15
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Serotype 35B
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Penicillin nonsusceptible isolates
Number of subjects: 228

Group type: COMPARATOR
Intervention: Earlier studies
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Serotypes 15 and 35B
Number of subjects: 228
Study: 24912106

Group type: EXPERIMENTAL
Intervention: Citalopram (open-label) for 8-14 weeks
Number of subjects: 2477
Study: 24912489

Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg PO daily) and Everolimus (10 mg PO daily)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Anastrozole and Everolimus
Number of subjects: 55
Study: 24912564

Group type: EXPERIMENTAL
Intervention: NIV adherence > 9 h/day
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: NIV adherence > 5 h/day
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: NIV adherence
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: NIV use > 9 h/day
Number of subjects: 213
Study: 24912660

Group type: EXPERIMENTAL
Intervention: Intestinal uptake of p-cresol (measured by 24 h urinary excretion of PCS)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Higher urinary excretion of PCS (per 100 μmol increase)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Urinary excretion of PCS (in multivariate analysis)
Number of subjects: 200
Study: 24912797

Group type: EXPERIMENTAL
Intervention: LY2189102 (0.6, 18, and 180 mg, SC)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: LY2189102 (0.02-2.5 mg/kg, IV)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: LY2189102 (IV and SC)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: LY2189102 (SC)
Number of subjects: 175
Study: 24913040

Group type: EXPERIMENTAL
Intervention: 10-item survey administered to patients
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 2-item tool based on beliefs about maintenance mesalamine and concerns about side effects
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: 2-item tool
Number of subjects: 106
Study: 24913066

Group type: EXPERIMENTAL
Intervention: Vandetanib (300 mg daily for a maximum of 10 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Historical cohort (not specified in the abstract)
Number of subjects: 20
Study: 24913160

Group type: EXPERIMENTAL
Intervention: XOMA 3AB
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 24913999

Group type: EXPERIMENTAL
Intervention: Antiplatelet and anticoagulant therapy strategies
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: High and intermediate bleeding risk procedures
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Anticoagulants
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Postoperative hemorrhagic complications
Number of subjects: 1134
Study: 24914044

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (cohort 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lenalidomide 15 mg/day plus Sunitinib 37.5 mg/day (cohort 3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day (MTD)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lenalidomide 10 mg/day plus Sunitinib 37.5 mg/day
Number of subjects: 16
Study: 24914098

Group type: EXPERIMENTAL
Intervention: extensively hydrolysed rice protein infant formula (eRHF)
Number of subjects: 39
Study: 24914120

Group type: EXPERIMENTAL
Intervention: Voriconazole and anidulafungin combination therapy
Number of subjects: 238

Group type: COMPARATOR
Intervention: Voriconazole monotherapy
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Anidulafungin treatment duration
Number of subjects: 238
Study: 24914492

Group type: EXPERIMENTAL
Intervention: Severe COPD exacerbation
Number of subjects: 44
Study: 24915120

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Day-night rhythm
Number of subjects: 122

Group type: COMPARATOR
Intervention: Standardized meal ingestion
Number of subjects: 122

Group type: COMPARATOR
Intervention: Gender comparison
Number of subjects: 122